Paul A, Cevc G, Bachhawat B K
Technische Universität München, Klinikum r.d.l., Germany.
Vaccine. 1998 Jan-Feb;16(2-3):188-95. doi: 10.1016/s0264-410x(97)00185-0.
Molecules greater than 500 Da normally do not cross the skin. This prevents epicutaneous delivery of the high molecular weight therapeutics as well as non-invasive transcutaneous immunisation. Extremely deformable vesicles prepared by the judicious combination of several materials provide a solution to this problem: the resulting agent carriers, transfersomes, are the only tested colloidal system that can transport even large macromolecules spontaneously through the skin in immunologically active form. Gap junction proteins (GJP) incorporated into transfersomes and applied to the intact skin surface thus give rise to specific antibody titres marginally higher than those elicited by subcutaneous injections of GJP in transfersomes, mixed lipid micelles or liposomes. The latter two carrier systems give no significant biological response after epicutaneous administration. Transcutaneous protein delivery by means of transfersomes also appears to increase the relative concentration of anti-GJP IgA in the serum.